EXPERIENCE OF BARICITINIB-REMDESIVIR USE IN PATIENTS WITH SARS-COV-2 INFECTION

M. GRAGERA GÓMEZ, C. REDONDO GALÁN, M.D. RIVAS RODRIGUEZ, A. ROJAS ALBARRÁN, A. GIL GARCÍA, J.F. RANGEL MAYORAL.
BAJAOZ UNIVERSITY HOSPITAL, PHARMACY, BADAJOZ, SPAIN
mercedes.gragera@salud-juntaex.es

Background and importance

The rapid emergence of SARS-CoV2 has led to the development of numerous treatments in a short period of time. The need for clinical expertise is vital for better care and follow-up of the hospitalized patient. Baricitinib and remdesivir are two treatments that can be used in combination and have been studied in some clinical trials.

Aim and objectives

Describe the clinical experience of the baricitinib - remdesivir combination in a tertiary hospital, as well as to analyze the adverse event (AE) profile.

Material and methods

Observational, descriptive, retrospective and multidisciplinary study of all patients treated with baricitinib-remdesivir

January 2020 to September 2021

✓ Clinical history
✓ Farmatools®

Results

<table>
<thead>
<tr>
<th>Total of patients with baricitinib remdesivir</th>
<th>50</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>34</td>
</tr>
<tr>
<td>Women</td>
<td>16</td>
</tr>
<tr>
<td>Average age (years)</td>
<td>66</td>
</tr>
<tr>
<td>Median days of hospitalización</td>
<td>10</td>
</tr>
<tr>
<td>Deaths</td>
<td>14</td>
</tr>
<tr>
<td>Not candidates of treatment</td>
<td>16</td>
</tr>
</tbody>
</table>

Adverse events:
- 11 infections
- 4 cardiotoxicity
- 4 hepatotoxicity
- 2 vascular events

Treatment was suspended in 4 patients

Of the 16 patients who did not fulfill treatment criteria, 6 presented an AE (37.5%)

Conclusion and relevance

32% of the patients were not candidates for treatment → It may increase the number of AEs. Treatment should be promoted and monitored only in patients who meet the inclusion criteria, which would lead to a much more efficient and safer pharmacotherapy.